Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pavirona** is an oral multi-ingredient nutraceutical tablet marketed for supportive management of cervical human papillomavirus infection. The product is described as containing quercetin, green tea extract, cinnamon extract, selenium, and licorice root extract, and is presented in the cited clinical literature as a fixed-composition phytochemical formulation intended to support HPV DNA clearance and cytologic regression during routine follow-up rather than replace standard gynecologic management. Its putative mechanism is multi-factorial and indirect, combining antiviral, antioxidant, immunomodulatory, and epithelial-recovery effects attributed to its constituent ingredients; preclinical rationale cited for the formulation includes suppression of HPV-related oncogenic signaling, modulation of oxidative stress pathways, and enhancement of host immune surveillance. The excerpt identifies the product as Papivir/Pavirona from Mealis and notes that the same ingredient composition has also been described under the separate product names Gene-Eden-VIR and Novirin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pavirona.